[1]孙宇馨,湛浩然,李心言,等.北京市稳定性冠心病患者疾病经济负担分析[J].卫生经济研究,2024,41(05):27-31.
　SUN Yuxin,ZHAN Haoran,LI Xinyan,et al.Study on Disease Economic Burden of Patients with Stable Coronary Artery Disease in Beijing[J].Journal Press of Health Economics Research,2024,41(05):27-31.
点击复制

北京市稳定性冠心病患者疾病经济负担分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年05期
页码:
27-31
栏目:
专题研究
出版日期:
2024-04-23

文章信息/Info

Title:
Study on Disease Economic Burden of Patients with Stable Coronary Artery Disease in Beijing
作者:
孙宇馨1; 湛浩然1; 李心言1; 徐婷婷1; 韩优莉1
1.首都医科大学公共卫生学院，北京 100069
Author(s):
SUN Yuxin;  ZHAN Haoran;  LI Xinyan;  XU Tingting;  HAN Youli
School of Public Health, Capital Medical University, Beijing 100069, China
关键词:
稳定性冠心病; 疾病经济负担; 北京市
Keywords:
stable coronary artery disease;  economic burden of disease;  Beijing
分类号:
R19
文献标志码:
A
摘要:
目的：测算北京市稳定性冠心病患者疾病经济负担。方法：通过调研北京市11家医疗机构稳定性冠心病患者费用清单，获得直接医疗经济负担数据；通过问卷调查，获得直接非医疗经济负担和间接经济负担数据；采用蒙特卡洛模拟进行疾病经济负担敏感性分析；采用微观模拟对疾病经济负担进行异质性分析。结果：冠心病患者人均年疾病经济负担为36 355.69元，其中直接医疗经济负担30 831.25元，直接非医疗经济负担4 318.53元，间接经济负担1 205.92元。分层分析发现，60岁以上患者疾病经济负担高于60岁以下患者。结论：北京市冠心病患者疾病经济负担较重，直接非医疗和间接经济负担也不容忽视，应提高冠心病诊断和治疗同质化水平，加强人群心脑血管疾病的预防与控制，减轻患者的疾病经济负担。
Abstract:
Objective To estimate the disease economic burden of patients with stable coronary artery disease(SCAD) in Beijing. Methods The direct medical burden data were obtained by investigating the diagnosis and treatment cost records of SCAD patients in 11 medical institutions in Beijing. The direct non-medical burden and indirect burden data were investigated by using self-made questionnaires among the patients. Monte Carlo simulation was used to analyze the sensitivity of total disease economic burden. The heterogeneity of the patients was analyzed by micro-simulation. Results The per capita annual economic burden of disease in SCAD patients was 36 355.69 yuan, of which 30 831.25 yuan was the direct medical economic burden, 4 318.53 yuan was the direct nonmedical economic burden, and 1 205.92 yuan was the indirect economic burden. Stratified analysis found that the disease economic burden of patients over 60 years old was higher than that of patients under 60 years old. Conclusion The SCAD patients in Beijing have a heavier disease economic burden, and the direct non-medical and indirect economic burden should not be ignored. It is necessary to improve the standardization of diagnosis and treatment of coronary heart diseases, strengthen the prevention and control of cardiovascular and cerebral vascular diseases in the population.

参考文献/References:

[1] 李延辉.冠心病研究进展系列讲座[J].人民军医，2007（07）：413-414.
[2] 国家卫生健康委员会.2022中国卫生健康统计年鉴[M].北京：中国协和医科大学出版社，2023.
[3] 马丽媛，王增武，樊静，等. 《中国心血管健康与疾病报告2021》要点解读[J]. 中国全科医学，2022，25（27）：3331-3346.
[4] Marquina C,Talic S,Vargas-Torres S,et al.Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029[J].Eur J Prev Cardiol,2022,29(08):1212-1219.
[5] 王国军，张亮，田庆丰，等.河南省农村居民冠心病的疾病经济负担分析[J].医学与社会，2008（11）：35-36，41.
[6] N?rgaard B L,Leipsic J,Gaur S,et al.Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps)[J].J Am Coll Cardiol,2014,63(12):1145-1155.
[7] Ko B S,Wong D T,N?rgaard B L, et al.Diagnostic performance of transluminal attenuation gradient and noninvasive fractional flow reserve derived from 320-detector row ct angiography to diagnose hemodynamically significant coronary stenosis:an nxt substudy[J].Radiology,2016,279(01):75-83.
[8] Liu X,Mo X,Zhang H,et al.A 2-year investigation of the impact of the computed tomography-derived fractional flow reserve calculated using a deep learning algorithm on routine decision-making for coronary artery disease management[J].Eur Radiol,2021,31(09):7039-7046.
[9] Chen S L,Ye F, Zhang J J,et al.Intravascular ultrasound-guided systematic two-stent techniques for coronary bifurcation lesions and reduced late stent thrombosis[J].Catheter Cardiovasc Interv,2013,81(03):456-463.
[10] Claessen B E,Mehran R,Mintz G S,Et al.Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents[J].JACC Cardiovasc Interv,2011,4(09):974-981.
[11] Gao X F,Kan J,Zhang Y J,Et al.Comparison of one-year clinical outcomes between intravascular ultrasound-guided versus angiography-guided implantation of drug-eluting stents for left main lesions: a single-center analysis of a 1,016-patient cohort[J].Patient Prefer Adherence,2014(08):1299-1309.
[12] Hong S J,Kim B K,Shin D H,et al.Usefulness of intravascular ultrasound guidance in percutaneous coronary intervention with second-generation drug-eluting stents for chronic total occlusions(from the Multicenter Korean-Chronic Total Occlusion Registry)[J].Am J Cardiol,2014,114(04):534-540.
[13] Tian J,Guan C,Wang W,et al.Intravascular ultrasound guidance improves the long-term prognosis in patients with unprotected left main coronary artery disease undergoing percutaneous coronary intervention[J].Sci Rep,2017,7(01):2377.
[14] Park S J,Kim Y H,Park D W,et al. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis[J].Circ Cardiovasc Interv,2009,2(03):167-177.
[15] Tonino P A,De Bruyne B,Pijls N H,et al.Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J].N Engl J Med,2009,360(03):213-224.
[16] Kim Y H,Her A Y,Rha S W,et al.Three-year major clinical outcomes of angiography-guided single stenting technique in non-complex left main coronary artery diseases[J].Int Heart J,2017,58(05):704-713.
[17] Toth G G,De Bruyne B,Kala P,et al.Graft patency after FFR-guided versus angiography-guided coronary artery bypass grafting: the GRAFFITI trial[J].EuroIntervention,2019,15(11):e999-e1005.
[18] Patel M R,N?覬rgaard B L,Fairbairn T A,et al.1-year impact on medical practice and clinical outcomes of ffr(ct): the advance registry[J].JACC Cardiovasc Imaging,2020,13:97-105.
[19] Baigent C,Blackwell L,Collins R,et al.Aspirin in the primary and secondary prevention of vascular disease:collaborative meta-analysis of individual participant data from randomised trials[J].Lancet,2009,373(9678):1849-1860.
[20] 王凡，胡晓洁，陈宇，等.海南省心血管疾病经济负担研究[J].卫生经济研究，2022，39（１１）：73-76.
[21] 秦江梅，张艳春，张丽芳，等.典型城市居民慢性病患病率及患者疾病负担分析[J].中国公共卫生，2014，30（０１）：5-7. [22] 李月，党媛媛，汤榕.冠心病患者住院费用及影响因素分析[J].中国病案，2022，23（０５）：48-51. [23] 范卢明.云南省农村居民常见心脑血管病疾病负担的变迁及影响因素研究[D].昆明：昆明医科大学，2022. [24] Smolderen K G,Wang K,De Pouvourville G,et al.Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany:highest burden for peripheral arterial disease[J].Eur J Vasc Endovasc Surg,2012,43(02):198-207. [25] Tonino P A,Fearon W F,De Bruyne B,et al.Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation[J].J Am Coll Cardiol,2010,55(25):2816-2821. [26] Min J K,Koo B K,Erglis A, et al. Usefulness of noninvasive fractional flow reserve computed from coronary computed tomographic angiograms for intermediate stenoses confirmed by quantitative coronary angiography[J].Am J Cardiol,2012,110(07):971-976. [27] Le C,Fang Y,Linxiong W,et al.Economic burden and cost determinants of coronary heart disease in rural southwest China:a multilevel analysis[J].Public Health,2015,129(01):68-73. [28] Darba S,Safaei N,Mahboub-Ahari A,et al.Direct and indirect costs associated with coronary artery (heart) disease in Tabriz, Iran[J].Risk Manag Healthc Policy,2020,13:969-978. [29] 《中国心血管健康与疾病报告2022》编写组.《中国心血管健康与疾病报告2022》要点解读[J].中国心血管杂志，2023，28（04）：297-312. [30] 韩雪.兰州市城区三级医院冠心病患者住院费用研究[D].兰州：兰州大学，2019. [31] Tyrovolas S,Tountas Y,Polychronopoulos E,et al.A classification and regression tree analysis for the evaluation of the role of nutritional services on cardiovascular disease risk status of older people living in Greek islands and Cyprus[J].Int J Food Sci Nutr,2012,63(05):522-529.

相似文献/References:

[1]于保荣,许 晴,刘 卓,等.新发传染病经济负担的方法学研究[J].卫生经济研究,2017,(07):25.
[2]王晓茹,李银山,王 瑶,等.宁南地区新农合大病患者医疗费用负担分析[J].卫生经济研究,2017,(10):30.
[3]于保荣,冯映雪,江陈庆,等.肿瘤疾病经济负担与健康保险政策研究[J].卫生经济研究,2018,(04):14.
[4]冷 瑶,李燕喃,邓 晶.我国中老年糖尿病患者的疾病经济负担分析[J].卫生经济研究,2018,(10):47.
　LENG Yao,LI Yan-nan,DENG Jing.Analysis of the Economic Burden of Diseases in Middle-aged and Elderly Patients with Diabetes in China[J].Journal Press of Health Economics Research,2018,(05):47.
[5]明星宇,杨 练,孙 群,等.四川省糖尿病疾病经济负担及影响因素分析[J].卫生经济研究,2019,(01):29.
　MING Xing-yu,YANG Lian,SUN Qun,et al.The Disease Economic Burden and Influence of Diabetes in Sichuan Province[J].Journal Press of Health Economics Research,2019,(05):29.
[6]董 辉,汤质如,严 训,等.安徽省恶性肿瘤治疗费用分析——基于“卫生费用核算体系2011”[J].卫生经济研究,2021,38(2):58.
　DONG Hui,TANG Zhi-ru,YAN Xun,et al.Analysis on Malignant Tumor Treatment Cost in Anhui Province——Based on the SHA 2011[J].Journal Press of Health Economics Research,2021,38(05):58.
[7]黎倩欣,周尚成,陈飘飘,等.深圳市糖尿病疾病经济负担研究[J].卫生经济研究,2021,38(3):63.
　LI Qian-xin,ZHOU Shang-cheng,CHEN Piao-piao,et al.Study on the Economic Burden of Diabetic Diseases in Shenzhen[J].Journal Press of Health Economics Research,2021,38(05):63.
[8]王佳卉,马增香.多囊卵巢综合征及其并发症的直接经济负担研究进展[J].卫生经济研究,2022,39(3):24.
　WANG Jia-hui,MA Zeng-xiang.Research Progress on Direct Economic Burden of Polycystic Ovary Syndrome and Its Complications[J].Journal Press of Health Economics Research,2022,39(05):24.
[9]李福明,夏 宇,魏 艳,等.晚期非小细胞肺癌初治患者的直接非医疗成本分析[J].卫生经济研究,2022,39(10):58.
　LI Fuming,XIA Yu,WEI Yan,et al.Analysis of Direct Non-medical Cost of Newly Treated Advanced Non-small Cell Lung Cancer Patients[J].Journal Press of Health Economics Research,2022,39(05):58.
[10]王 凡,胡晓洁,陈 宇,等.海南省心血管疾病经济负担研究[J].卫生经济研究,2022,39(11):73.
　WANG Fan,HU Xiaojie,CHEN Yu,et al.Study on the Economic Burden of Cardiovascular Disease in Hainan Province[J].Journal Press of Health Economics Research,2022,39(05):73.

更新日期/Last Update: 2024-04-23